Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

severe hypertriglyceridemia

- PMLiVE

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival

- PMLiVE

FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants

The authorisation is specifically for the children aged six months to four years

- PMLiVE

Eli Lilly and Incyte’s Olumiant receives FDA approval for alopecia

The treatment is the first and only systemic medicine for adults with the condition

- PMLiVE

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

The vaccine has been approved to use in those aged 12 months and above

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

Sanofi and Regeneron receives FDA priority review for prurigo nodularis

Dupixent would be the first drug specifically indicated for the condition in the US

- PMLiVE

Genentech’s Evrysdi gets extended FDA approval for spinal muscular atrophy

The drug is now approved to treat SMA in children and adults of all ages

- PMLiVE

Novartis’ Kymriah receives FDA approval to treat follicular lymphoma

The CAR-T cell treatment is approved for adult patients who have had two or more previous therapies

- PMLiVE

Phase 3 trial initiated to evaluate AZ’s Saphnelo in lupus nephritis

The antibody has already been approved to treat systemic lupus erythematosus

- PMLiVE

Dermavant’s Vtama receives FDA approval for plaque psoriasis

It is the first topical steroid-free cream to be granted FDA approval in its class

- PMLiVE

Results released from new study of AstraZeneca’s COVID-19 antibody

A new study from Oxford University shows that Evusheld is effective in protecting against emerging Omicron variants

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links